APVO442 (PSMA x CD3):
A Preclinical Program Utilizing ADAPTIR-FLEX to Target PSMA with High Affinity, and to CD3 with Low Affinity, for The Treatment of Prostate Cancer
Status: Preclinical Development
Highlights
- APVO442 is built on Aptevo’s ADAPTIR-FLEX platform and leverages the unique properties of this technology to increase binding to tumor antigen while having lower binding to T cells in circulation
- The drug candidate designed to target Prostate Specific Membrane Antigen (PSMA). PSMA is a tumor antigen that is highly expressed on prostate cancer cells with limited normal tissue expression
- Our uniqueCD3, a signaling component of the T cell receptor complex has been detuned for reduced binding affinity, while retaining high functionality
The Molecule
APVO442 is designed to maximize anti-tumor responses:
- Optimized to increase bio-distribution to tumor: Low affinity, monovalent CD3 engagement is designed to reduce binding to peripheral T cells expressing CD3. The high affinity, bivalent anti-PSMA binding is designed to increase concentration of the drug at the tumor site to engage tumor-resident T cells.
- Reduced cytokine release: CD3-targeting therapeutics designed on the ADAPTIR-FLEX platform are like those designed on the ADAPTIR platform in that they retain high potency tumor killing based on preclinical studies while maintaining reduced cytokine release measured in controlled in vitro analyses. This approach may provide a safer and more tolerable treatment for patients with prostate cancer.
The ADAPTIR-FLEX™ platform technology in combination with our unique anti-CD3 can be utilized to target addition solid tumor antigens with the potential to improve responses in additional solid tumor indications.
View APVO442 Scientific Presentations Here:
https://aptevotherapeutics.gcs-web.com/presentations